Reportlinker Adds Epidemiology: Insomnia

Wednesday, May 11, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, May 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Epidemiology:

Insomnia

http://www.reportlinker.com/p0491920/Epidemiology-Insomnia.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Introduction

In this analysis, Datamonitor estimates that there were a

total of 53 million cases of insomnia in 2010 in the seven major markets with nearly a half of these cases present in the US. Prevalence rates for insomnia are expected to remain constant; therefore, any changes in prevalence will depend on population dynamics in the seven major healthcare markets

Features and benefits

* Gain insight to market potential, including a robust 10-year epidemiology forecast of prevalent insomnia cases.

* Understand the key epidemiologic risk factors associated with insomnia.

Highlights

Datamonitor expects an increase in prevalent insomnia cases in the next decade in the seven major markets as a result of an ageing population.

Unsatisfactory sleep can cause severe distress and cause social, interpersonal, and occupational impairment.

Your key questions answered

* What are the most robust epidemiologic studies for insomnia prevalence data?

* How will the patient population change over the next decade in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK)?

* How do changes in population structure and risk factors affect the trend in prevalent insomnia cases?

Executive Summary

Strategic scoping and focus

Datamonitor key findings

Related reports

OVERVIEW

Catalyst

Summary

CLINICAL PIPELINE OVERVIEW

Overview of the depression pipeline

Datamonitor has identified 46 separate programs in clinical development

Emerging features of the depression pipeline

Changes in pipeline dynamics

Companies involved in the depression pipeline

Late-stage development compounds recently discontinued

TARGET PRODUCT PROFILE

Comparator therapies

Lexapro (escitalopram; Forest/Lundbeck)

Target product profile versus current level of attainment

CLINICAL TRIAL DESIGN IN DEPRESSION

Clinical trials

Commonly used clinical trial endpoints for depression

Typical trial design

Trial length is commonly standardized to a duration of just 8 weeks

Comparator trials can provide a compelling argument for using one drug ahead of another

Future developments in clinical trial design

Treatment-resistant depression clinical trial design

Adjunctive therapy clinical trial design

INNOVATIVE EARLY-STAGE APPROACHES

Glutamate receptor modulation

NMDA receptor antagonists and partial agonists

Metabotropic glutamate receptor antagonists

Targeting neuropeptides for depression

Background

Vasopressin receptor antagonists

Corticotropin-releasing factor receptor antagonists

Neurokinin receptor antagonists

THE FUTURE OF TREATMENT IN DEPRESSION

Specific targeting of treatment-resistant patients

A label for treatment-resistant depression will bypass competition with generic first-line antidepressants

Treatment-resistant depression is characterized by a large target population and substantial unmet need

Biomarkers for depression

Considerable variations in treatment outcomes exist

Biomarkers may have utility in identifying appropriate patients and improving treatment outcomes

The commercial appeal of reduced R&D spend and a competitive advantage is a bonus

Biomarkers in clinical development

BIBLIOGRAPHY

Journal papers

Websites

Datamonitor reports

APPENDIX

Contributing experts

Conferences attended

Report methodology

To order this report:

Pathology Industry: Epidemiology: Insomnia

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store